ES2057145T3 - Formulaciones parenterales de 1-difenilmetil-4-((2-(4-metil-fenil)-5-metil-1h-imidazol-4-il)-metil)piperazin. - Google Patents

Formulaciones parenterales de 1-difenilmetil-4-((2-(4-metil-fenil)-5-metil-1h-imidazol-4-il)-metil)piperazin.

Info

Publication number
ES2057145T3
ES2057145T3 ES89310852T ES89310852T ES2057145T3 ES 2057145 T3 ES2057145 T3 ES 2057145T3 ES 89310852 T ES89310852 T ES 89310852T ES 89310852 T ES89310852 T ES 89310852T ES 2057145 T3 ES2057145 T3 ES 2057145T3
Authority
ES
Spain
Prior art keywords
methyl
diphenyl
piperazin
imidazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89310852T
Other languages
English (en)
Inventor
Alastair B Selkirk
Michael J Dey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex Pharmaceuticals International Ltd
Syntex Pharmaceuticals Ltd
Original Assignee
Syntex Pharmaceuticals International Ltd
Syntex Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Pharmaceuticals International Ltd, Syntex Pharmaceuticals Ltd filed Critical Syntex Pharmaceuticals International Ltd
Application granted granted Critical
Publication of ES2057145T3 publication Critical patent/ES2057145T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

UNA FORMULACION FARMACEUTICA ADECUADA PARA ADMINISTRACION PARENTERAL (PREFERIBLEMENTE INTRAVENOSA) INCLUYE UNA CANTIDAD EFECTIVA DE 1-DIFENILMETIL-4-[(2-(METILFENIL)-5-METIL-1HIMIDAZOL-4-IL)METIL]PIPERACINA Y UNA CANTIDAD ADECUADA DE UN ACIDO PARA GENERAR UNA SAL FARMACEUTICAMENTE ACEPTABLE TENIENDO UN PH SOBRE ALREDEDOR DE 3,0 Y UNA SOLUBILIDAD DE ALREDEDOR DE 4,0 MG/ML. LA FORMULACION INTRAVENOSA INCLUYE OPCIONALMENTE UN TONIFICADOR ADECUADO EN UNA CANTIDAD SUFICIENTE PARA CONSEGUIR ISOTONICIDAD CON CUERPOS FLUIDOS. LA SAL SE FORMA "IN SITU" DURANTE EL PROCESO DE FORMULACION. SE PREFIERE LA SAL DE ACIDO TARTARICO; SALES ADECUADAS PARA DOSIS DE MENORES CONCENTRACIONES SON EL ACIDO CITRICO Y SALES ACIDAS METANO SULFONICAS.
ES89310852T 1988-10-21 1989-10-20 Formulaciones parenterales de 1-difenilmetil-4-((2-(4-metil-fenil)-5-metil-1h-imidazol-4-il)-metil)piperazin. Expired - Lifetime ES2057145T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/260,628 US4973591A (en) 1988-10-21 1988-10-21 Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine

Publications (1)

Publication Number Publication Date
ES2057145T3 true ES2057145T3 (es) 1994-10-16

Family

ID=22989940

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89310852T Expired - Lifetime ES2057145T3 (es) 1988-10-21 1989-10-20 Formulaciones parenterales de 1-difenilmetil-4-((2-(4-metil-fenil)-5-metil-1h-imidazol-4-il)-metil)piperazin.

Country Status (14)

Country Link
US (1) US4973591A (es)
EP (1) EP0365363B1 (es)
JP (1) JPH02157224A (es)
KR (1) KR900005962A (es)
AT (1) ATE88094T1 (es)
AU (1) AU636581B2 (es)
CA (1) CA2001170A1 (es)
DE (1) DE68905995T2 (es)
DK (1) DK523389A (es)
ES (1) ES2057145T3 (es)
GR (1) GR3007663T3 (es)
IE (1) IE63292B1 (es)
NZ (1) NZ231094A (es)
ZA (1) ZA897975B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK178590D0 (da) * 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
US5276035A (en) * 1990-07-26 1994-01-04 Novo Nordisk A/S 1,4-disubstituted piperazines
SE469717B (sv) * 1992-02-20 1993-08-30 Ingemar Naeslund Klaemma, speciellt foer tillslutning av paasar
CA2163966A1 (en) * 1993-06-01 1994-12-08 Judith A. Kelleher Alkaline and acid phosphatase inhibitors in treatment of neurological disorders
EP1683519A4 (en) * 2003-11-14 2009-04-01 Mochida Pharm Co Ltd PREVENTIVE / THERAPEUTIC AGENT FOR TREATING SPEECH DISORDERS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
GB1184714A (en) * 1965-12-16 1970-03-18 Science Union & Cie Di- and Tri-Phenylpropyl Piperazine Derivatives
US3491098A (en) * 1967-05-29 1970-01-20 Sterling Drug Inc 1-((imidazolyl)-lower-alkyl)-4-substituted-piperazines
DE1795314A1 (de) * 1968-09-11 1972-01-05 Merck Patent Gmbh N-(Thiazolyl-2)-piperazine
US3927011A (en) * 1973-05-10 1975-12-16 Yoshitomi Pharmaceutical 2-Aminoalkyl-1-(pyridylcarbonylphenyl)imidazole compounds
US4022783A (en) * 1975-10-29 1977-05-10 Usv Pharmaceutical Corporation Piperazinyl-imidazolines
GB1551993A (en) * 1976-09-21 1979-09-05 Malesci Sas Pharmacologiclly active derivatives of 1 alkyl 4-phenylpiperazines and the preparation thereof
IT1159698B (it) * 1978-05-29 1987-03-04 Rotta Research Lab Derivati 5-nitro-imidazolici della piperazina ad attivita' antiprotozoica
US4243806A (en) * 1979-06-13 1981-01-06 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
US4404382A (en) * 1980-09-17 1983-09-13 The Upjohn Company Piperazinyl-substituted imidazoles
HU187399B (en) * 1980-12-24 1985-12-28 Sumitomo Chemical Co Process for preparing imidazolyl-propanol derivatives
US4435399A (en) * 1981-07-18 1984-03-06 Pfizer Inc. 2-Aryl-1-(imidazol-1-yl)-8-(4-piperazin-1-ylphenoxy) octan-2-ol antifungal agents
US4829065A (en) * 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives

Also Published As

Publication number Publication date
DK523389D0 (da) 1989-10-20
ATE88094T1 (de) 1993-04-15
AU4356989A (en) 1990-04-26
DE68905995D1 (de) 1993-05-19
IE893382L (en) 1990-04-21
EP0365363B1 (en) 1993-04-14
ZA897975B (en) 1991-06-26
GR3007663T3 (es) 1993-08-31
US4973591A (en) 1990-11-27
CA2001170A1 (en) 1990-04-21
DK523389A (da) 1990-04-22
EP0365363A1 (en) 1990-04-25
NZ231094A (en) 1991-12-23
JPH02157224A (ja) 1990-06-18
DE68905995T2 (de) 1993-09-16
AU636581B2 (en) 1993-05-06
KR900005962A (ko) 1990-05-07
IE63292B1 (en) 1995-04-05

Similar Documents

Publication Publication Date Title
US6238689B1 (en) Intestinal absorption of nicotine to treat nicotine responsive conditions
NO174412C (no) Fremgangsmåte for fremstilling av en farmasöytisk formulering med programmert frigjöring for oral anvendelse
IE61068B1 (en) Mixed micelle solutions containing non-steroidal anti-inflammatories
UA41502C2 (uk) Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
LU91037I2 (fr) Somatulina autogel
JPWO1999002158A1 (ja) ４，５−エポキシモルヒナン誘導体を含有する安定な医薬品組成物
GB2189994A (en) Pharmaceutical compositions containing ibuprofen
KR910007511A (ko) 콜라겐 함유 안약 제형
CA2215327A1 (en) Formulations for lipophilic compounds
US4883805A (en) Stable, Injectable solutions of vinca dimer salts
JP2000273061A (ja) テルペノイドエマルション
DE58906232D1 (de) Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe.
YU86792A (sh) Rastvor sparfloksacina, njegovo dobijanje i so sparfloksacina kao komponenta rastvora
JPH02326B2 (es)
JPH06247872A (ja) 高濃度ｔｃｆ製剤
IE893382L (en) Parenteral Formulations of¹1-Diphenylmethyl-4-£(2-(4-Methylphenyl)-5¹Methyl-1H-Imidazol-4-YL) Methyl| Piperazine
CA1335076C (en) Pharmaceutical composition and method for intranasal administration
MX9302711A (es) Preparacion de base.
US3849558A (en) Pharmaceutical compositions having controlled gastro-intestinal absorption
US3767803A (en) Stable aqueous pyritinol solutions
JP2001172183A (ja) 眼科用医薬組成物
SE8501312D0 (sv) Etoposide oral dosage form
ATE45090T1 (de) Pharmazeutische zusammensetzung in oralen darreichungsformen.
US3962436A (en) Pharmaceutical compositions having controlled rate of gastro-intestinal absorption
IT1244660B (it) Preparati farmaceutici per la terapia dei tumori contenenti colchicina come principio attivo e metodi per l'impiego degli stessi.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 365363

Country of ref document: ES